Panoramic Capital LLC Invests $10.77 Million in Axsome Therapeutics, Inc. $AXSM

Panoramic Capital LLC acquired a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 44,000 shares of the company’s stock, valued at approximately $10,770,000. Axsome Therapeutics comprises 4.6% of Panoramic Capital LLC’s investment portfolio, making the stock its 6th largest holding.

Other institutional investors and hedge funds have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Axsome Therapeutics by 4.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock valued at $2,557,000 after purchasing an additional 1,002 shares during the last quarter. Jones Financial Companies Lllp raised its position in shares of Axsome Therapeutics by 2,407.9% during the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock valued at $889,000 after buying an additional 7,320 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Axsome Therapeutics by 38.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock valued at $35,189,000 after buying an additional 84,151 shares in the last quarter. Caxton Associates LLP bought a new stake in shares of Axsome Therapeutics during the 1st quarter worth $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Axsome Therapeutics by 29.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock worth $8,735,000 after acquiring an additional 17,250 shares during the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on AXSM shares. UBS Group reissued a “buy” rating on shares of Axsome Therapeutics in a research note on Monday. Wells Fargo & Company lifted their price target on Axsome Therapeutics from $255.00 to $256.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. Jefferies Financial Group reiterated a “buy” rating and issued a $380.00 price objective on shares of Axsome Therapeutics in a report on Thursday, June 11th. Oppenheimer set a $280.00 price objective on Axsome Therapeutics in a research report on Monday, May 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $267.60.

Axsome Therapeutics Stock Performance

Axsome Therapeutics stock opened at $207.15 on Thursday. The firm has a fifty day simple moving average of $229.34 and a two-hundred day simple moving average of $206.61. The company has a quick ratio of 1.34, a current ratio of 1.43 and a debt-to-equity ratio of 1.52. Axsome Therapeutics, Inc. has a twelve month low of $112.90 and a twelve month high of $260.19. The company has a market capitalization of $10.85 billion, a PE ratio of -55.24 and a beta of 0.65.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. The company had revenue of $218.38 million for the quarter, compared to the consensus estimate of $221.11 million. Research analysts expect that Axsome Therapeutics, Inc. will post -2.8 EPS for the current year.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating on Axsome Therapeutics, signaling continued confidence in the company’s long-term commercial outlook despite lowering its earnings forecasts.
• Neutral Sentiment: The firm continues to project a significant improvement in profitability in 2027, with positive earnings expected beginning in the second quarter and full-year 2027 EPS forecast at $5.25.
• Neutral Sentiment: A report showing zero short interest as of August 25 does not indicate meaningful short-selling pressure, although the data appears inconsistent because it also reports no change from the prior period.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to a loss of $4.10 from a loss of $3.89, while cutting forecasts for third-quarter and fourth-quarter 2026 EPS to losses of $0.95 and $0.91, respectively.
• Negative Sentiment: The analyst also lowered its 2027 estimates: first-quarter EPS was revised to a $0.27 loss from $0.05 in earnings, second-quarter EPS to $1.06 from $1.30, third-quarter EPS to $1.92 from $2.30, and full-year EPS to $5.25 from $6.47. Fourth-quarter 2027 EPS was reduced to $2.53 from $2.81.

Insider Buying and Selling

In other Axsome Therapeutics news, CFO Nick Pizzie sold 33,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $240.09, for a total value of $7,922,970.00. Following the completion of the sale, the chief financial officer owned 42,867 shares in the company, valued at approximately $10,291,938.03. The trade was a 43.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mark Coleman sold 6,000 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $230.30, for a total value of $1,381,800.00. Following the sale, the director directly owned 35,140 shares of the company’s stock, valued at approximately $8,092,742. This trade represents a 14.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 200,766 shares of company stock valued at $46,685,646 in the last 90 days. 20.60% of the stock is owned by insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.